COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review

Maryam Sharifian-Dorche, Mohammad Ali Sahraian, Giulia Fadda, Michael Osherov, Amirhossein Sharifian-Dorche, Maryam Karaminia, Alexander William Saveriano, Roberta La Piana, Jack P Antel, Paul Steven Giacomini, Maryam Sharifian-Dorche, Mohammad Ali Sahraian, Giulia Fadda, Michael Osherov, Amirhossein Sharifian-Dorche, Maryam Karaminia, Alexander William Saveriano, Roberta La Piana, Jack P Antel, Paul Steven Giacomini

Abstract

Introduction: The Coronavirus disease-19 (COVID-19) pandemic continues to expand across the world. This pandemic has had a significant impact on patients with chronic diseases. Among patients with demyelinating diseases of the central nervous system (CNS), such as Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD), concerns remain about the potential impact of COVID-19 on these patients given their treatment with immunosuppressive or immunomodulatory therapies. In this study, we review the existing literature investigating the impact of disease-modifying therapies(DMT) on COVID-19 risks in this group of patients.

Method: For this systematic review, we searched PubMed from January 1, 2020, to December 3, 2020. The following keywords were used: "COVID-19" AND "Multiple Sclerosis" OR "Neuromyelitis Optica." Articles evaluating COVID-19 in patients with demyelinating diseases of CNS were included. This study evaluates the different aspects of the DMTs in these patients during the COVID-19 era.

Results and conclusion: A total of 262 articles were found. After eliminating duplicates and unrelated research papers, a total of 84 articles met the final inclusion criteria in our study. Overall, the experiences of 2493 MS patients and 37 NMOSD patients with COVID-19 were included in this review. Among them, 46(1.8%) MS patients died(the global death-to-case ratio of Covid-19 was reported about 2.1%). Among DMTs, Rituximab had the highest mortality rate (4%). Despite controversies, especially concerning anti-CD20 monoclonal antibody therapies, a relation between DMT-use and COVID-19 disease- course was not found in many studies. This observation reinforces the recommendation of not stopping current DMTs. Other variables such as age, higher expanded disability status scale (EDSS) scores, cardiac comorbidities, and obesity were independent risk factors for severe COVID-19. Despite the risks of infection, most patients were willing to continue their DMT during the pandemic because of more significant concern about the risk of relapse or worsening MS symptoms. After the infection, an immune response's attenuation was seen in the patients on Fingolimod and anti-CD20 monoclonal antibodies. This may be a critical finding in future vaccinations.

Keywords: COVID-19; Disease-modifying therapies; Multiple sclerosis; Neuromyelitis optica spectrum disorder.

Conflict of interest statement

None.

Copyright © 2021. Published by Elsevier B.V.

Figures

Fig. 1.
Fig. 1.
PRISMA chart of this study. *Among the selected articles, those with relation to the rate of infection in patients on DMTs, articles related to psychiatric problems and anxiety in MS and NMOSD patients during pandemic (with focus on the articles which evaluated the risk of different DMT and attitude of the patients about continuing or discontinuing of the DMT) and articles related to vaccination were included. Other articles were excluded (to have a more focused review).
Fig. 2.
Fig. 2.
SARS-CoV-2 inhibits the antiviral type 1 IFN molecules' production by the infected cells and the intracellular antioxidant NRF2 pathway. GA causes a shift from a pro-inflammatory to an anti-inflammatory response. DMF blocks pro-inflammatory cytokine production and can inhibit macrophage function. Teriflunomide may affect the replication of SARS-CoV-2 inside the infected cell. Fingolimod enhancing lung endothelial cell integrity. Natalizumab as an antibody against α4- integrin might be protective toward the infection. Anti-CD20 monoclonal antibodies moderately reduced immune response by peripheral B cell reduction, which might play a favorable role in COVID-19. Designed with https://biorender.com/ . ARDS: Acute respiratory distress syndrome , GA: Glatiramer acetate, DMF: Dimethyl fumarate, IFN: Interferon beta. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3.
Fig. 3.
Prevalence of reported MS patients with COVID-19 on different DMTs, categorized according to the risk of infection. DMF: Dimethyl fumarate, GA: Glatiramer acetate, Ter: Teriflunomide, Nat: Natalizumab, Al: Alemtuzumab,Ocr: Ocrelizumab, Cladri: Cladribine, Rituxi:Rituximab,Fingo:Fingolimod, INF: Interferon beta.
Fig. 4
Fig. 4
Prevalence of reported mortality in MS patients with COVID-19 on different DMTs (On Med), without medication (No Med), or undetermined (Undet) groups. (In this chart, we divided the mortality case in each group by the total number of patients who died(46 patients)). DMF: Dimethyl fumarate, GA: Glatiramer acetate, Ter: Teriflunomide, Nat: Natalizumab, Ocr: Ocrelizumab, Rituxi:Rituximab,Fingo:Fingolimod.

References

    1. Aguirre C., Meca-Lallana V., Barrios-Blandino A., Del Río B., Vivancos J. Covid-19 in a patient with multiple sclerosis treated with Natalizumab: may the blockade of integrins have a protective role? Mult. Scler. Relat. Disord. 2020;44 June 3.
    1. Amor S., Baker D., Khoury S.J., Schmierer K., Giovanonni G. SARS-CoV-2 and multiple sclerosis: not all immune depleting DMTs are equal or bad. Ann. Neurol. 2020 PMID: 32383812.
    1. Baker D., Roberts C.A.K., Pryce G., Kang A.S., Marta M., Reyes S., et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin. Exp. Immunol. 2020 doi: 10.1111/cei.13495. Jul 16doi: 10.1111/cei.13495.
    1. Bar-Or A., Calkwood J.C., Chognot C., Evershed J., Fox E.J., Herman A., et al. Effect of Ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95(14):e1999–e2008. doi: 10.1212/WNL.0000000000010380. Oct 6Epub 2020 July 29.
    1. Barzegar M., Mirmosayyeb O., Ghajarzadeh M., Nehzat N., Vaheb S., Shaygannejad V., et al. Characteristics of COVID-19 disease in multiple sclerosis patients. Mult. Scler. Relat. Disord. 2020;45 doi: 10.1016/j.msard.2020.102276. June 8.
    1. Barzegar M., Mirmosayyeb O., Nehzat N., Sarrafi R., Khorvash F., Maghzi A.H., et al. COVID-19 infection in a patient with multiple sclerosis treated with Fingolimod. Neurol. Neuroimmunol. Neuroinflamm. 2020;7(4):e753. May 5.
    1. Berger J.R., Brandstadter R. Bar-Or A. COVID-19 and MS disease-modifying therapies. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e761.
    1. Bollo L., Guerra T., Bavaro D.F., Monno L., Saracino A., Angarano G., et al. seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with Fingolimod and teriflunomide. J. Neurol. Sci. 2020;416 doi: 10.1016/j.jns.2020.117011. July 4.
    1. Borriello G., Ianniello A. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. Mult. Scler. Relat. Disord. 2020;41 Apr 30.
    1. Bowen J.D., Brink J., Brown T.R., Lucassen E.B., Smoot K., Wundes A., et al. COVID-19 in MS: initial observations from the Pacific Northwest. Neurol. Neuroimmunol. Neuroinflamm. 2020;7(5):e783. May 26.
    1. Capuano R., Altieri M., Bisecco A., d’Ambrosio A., Docimo R., Buonanno D., et al. Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience? J. Neurol. 2020:1–8. doi: 10.1007/s00415-020-10099-9. Jul 28.
    1. Carandini T., Pietroboni A.M., Sacchi L., De Riz M.A., Pozzato M., Arighi A., et al. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: a mild, uncomplicated infection despite intense immunosuppression. Mult. Scler. 2020 May 281352458520926459.
    1. Castillo Álvarez F., López Pérez M.Á., Marzo Sola M.E. Risk of SARS-CoV-2 infection and clinical outcomes in multiple sclerosis patients in La Rioja (Spain): [es]Riesgo de infección por SARS-CoV-2 y resultados clínicos en pacientes con Esclerosis Múltiple en la Rioja (España). Med. Clin. (Engl. Ed). 2020 doi: 10.1016/j.medcle.2020.06.017. Oct 1.
    1. Celius E.G. Normal antibody response after COVID-19 during treatment with Cladribine. Mult. Scler. Relat. Disord.. 2020;46 doi: 10.1016/j.msard.2020.102476. August 29.
    1. Chaudhry F., Bulka H., Rathnam A.S., Said O.M., Lin J., Lorigan H., et al. COVID-19 in multiple sclerosis patients and risk factors for severe infection. J. Neurol. Sci. 2020;418 doi: 10.1016/j.jns.2020.117147. September 19.
    1. Chiaravalloti N.D., Amato M.P., Brichetto G., Chataway J., Dalgas U., DeLuca J., et al. The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis. J. Neurol. 2020:1–10. doi: 10.1007/s00415-020-10160-7. Aug 19.
    1. Chiarini M., Paghera S., Moratto D., Rossi N., Giacomelli M., Badolato R., et al. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection. J. Neuroimmunol. 2020;345 doi: 10.1016/j.jneuroim.2020.577282. August 15Epub 2020 May 29.PMID: 32505908.
    1. Ciampi E., Uribe-San-Martin R., Cárcamo C. COVID-19 pandemic: the experience of a multiple sclerosis centre in Chile. Mult. Scler. Relat. Disord. 2020;42 May 16.
    1. Ciampi E., Uribe-San-Martín R., Soler B., Fernández R., García P., Navarrete-Asenjo C., et al. COVID-19 in MS and NMOSD: a multicentric online national survey in Chile. Mult. Scler. Relat. Disord. 2020;45 doi: 10.1016/j.msard.2020.102392. Jul 12.
    1. Ciardi M.R., Zingaropoli M.A., Pasculli P., Perri V., Tartaglia M., Valeri S., et al. The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia. J. Neuroimmunol. 2020;346 doi: 10.1016/j.jneuroim.2020.577323. July 15.
    1. Ciotti J.R., Valtcheva M.V., Cross A.H. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult. Scler. Relat. Disord. 2020;45 doi: 10.1016/j.msard.2020.102439. August 1.
    1. Conte W.L. Attenuation of antibody response to SARS-CoV-2 in a patient on Ocrelizumab with hypogammaglobulinemia. Mult. Scler. Relat. Disord.. 2020;44 June 20.
    1. “COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)”. ArcGIS. Johns Hopkins University. Retrieved 11 January 2021. .
    1. Creed M.A., Ballesteros E., Jr L.J.G., Imitola J. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder. Mult. Scler. Relat. Disord. 2020;44 May 19.
    1. Crescenzo F., Marastoni D., Bovo C., Calabrese M. Frequency and severity of COVID-19 in multiple sclerosis: a short single-site report from northern Italy. Mult. Scler. Relat. Disord. 2020;44 doi: 10.1016/j.msard.2020.102372. July 4.
    1. Dalla Costa G., Leocani L., Montalban X., Guerrero A.I., Sørensen P.S., Magyari M., et al. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multi-center European study. Neurol. Sci. 2020;41(7):1647–1650. doi: 10.1007/s10072-020-04519-x. Jul.
    1. De Angelis M., Petracca M., Lanzillo R., Brescia Morra V., Moccia M. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: two cases and implications for clinical practice. Mult. Scler. Relat. Disord.. 2020;45 doi: 10.1016/j.msard.2020.102452. August 16.
    1. Delbue S., Guerini F.R., Mancuso R., Caputo D., Mazziotti R., Saresella M., et al. JC virus viremia in interferon-beta-treated and untreated Italian multiple sclerosis patients and healthy controls. J. Neurovirol. 2007;13:73–77.
    1. Demir C.F., Bilek F., Balgetir F. Neuropsychiatric changes during the COVID-19 pandemic in multiple sclerosis patients. Arq. Neuropsiquiatr. 2020 doi: 10.1590/0004-282X20200122. Sep 23S0004-282X2020005023202.
    1. Dersch R., Wehrum T., Fähndrich S., Engelhardt M., Rauer S., Berger B. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. Mult. Scler. 2020;26(10):1264–1266. doi: 10.1177/1352458520943783. Sep.
    1. Devogelaere J., D’hooghe M.B., Vanderhauwaert F., D’haeseleer M. Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis. Neurol. Sci. 2020;41(8):1981–1983. Aug.
    1. Evangelou N., Garjani A., dasNair R., Hunter R., Tuite-Dalton K.A., Craig E.M., et al. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. J. Neurol. Neurosurg. Psychiatry. 2020 doi: 10.1136/jnnp-2020-324449. Aug 27jnnp-2020-324449.
    1. Fan M., Qiu W., Bu B., Xu Y., Yang H., Huang D., et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol. Neuroimmunol. Neuroinflamm. 2020;7(5):e787. June 4.
    1. Fernández-Díaz E., Gracia-Gil J., García-García J.G., Palao M., Romero-Sánchez C.M., Segura T. COVID-19 and multiple sclerosis: a description of two cases on alemtuzumab. Mult. Scler. Relat. Disord.. 2020;45 doi: 10.1016/j.msard.2020.102402. Jul 17.
    1. Fiorella C., Lorna G. COVID-19 in a multiple sclerosis (MS) patient treated with Alemtuzumab: insight to the immune response after COVID. Mult. Scler. Relat. Disord.. 2020;46 doi: 10.1016/j.msard.2020.102447. August 10.
    1. Foerch C., Friedauer L., Bauer B., Wolf T., Adam E.H. Severe COVID-19 infection in a patient with multiple sclerosis treated with Fingolimod. Mult. Scler. Relat. Disord. 2020;42 May 6.
    1. Ghaderi S., Berg-Hansen P., Bakken I.J., Magnus P., Trogstad L., Håberg S.E. Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway. Eur. J. Epidemiol. 2020;35(4):355–362. doi: 10.1007/s10654-019-00595-2. AprEpub 2019 December 23.
    1. Ghajarzadeh M., Mirmosayyeb O., Barzegar M., Nehzat N., Vaheb S., Shaygannejad V., et al. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on Ocrelizumab during the pandemic. Mult. Scler. Relat. Disord. 2020;43 May 23.
    1. Giovannoni G., Hawkes C., Lechner-Scott J., Levy M., Waubant E., Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult. Scler. Relat. Disord. 2020 PMID: 32334820.
    1. Gomez-Mayordomo V., Montero-Escribano P., Matías-Guiu J.A., González-García N., Porta-Etessam J., Matías-Guiu J. Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal. J. Med. Virol. 2020 doi: 10.1002/jmv.26279. Jul 9doi: 10.1002/jmv.26279. Online ahead of print.PMID: 32644205.
    1. Guevara C., Villa E., Cifuentes M., Naves R., Grazia J. Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to Alemtuzumab. Mult. Scler. Relat. Disord.. 2020;44 doi: 10.1016/j.msard.2020.102314. June 20.
    1. Haji Akhoundi F., Sahraian M.A., Naser Moghadasi A. Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients. Mult. Scler. Relat. Disord.. 2020;41 doi: 10.1016/j.msard.2020.102164. JunEpub 2020 April 29.
    1. Hughes R., Pedotti R., Koendgen H. COVID-19 in persons with multiple sclerosis treated with Ocrelizumab - A pharmacovigilance case series. Mult. Scler. Relat. Disord. 2020;42 May 16.
    1. Hutton B., Salanti G., Caldwell D.M. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 2015;162:777–784.
    1. Iannetta M., Cesta N., Stingone C., Malagnino V., Teti E., Vitale P., et al. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with Ocrelizumab. Mult. Scler. Relat. Disord.. 2020;45 doi: 10.1016/j.msard.2020.102442. August 4.
    1. Jack D., Nolting A., Galazka A. Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets. Mult. Scler. Relat. Disord.. 2020;46 doi: 10.1016/j.msard.2020.102469. August 27.
    1. Kataria S., Tandon M., Melnic V., Sriwastava S. A case series and literature review of multiple sclerosis and COVID-19: clinical characteristics, outcomes and a brief review of immunotherapies. eNeurologicalSci. 2020;21 doi: 10.1016/j.ensci.2020.100287. DecEpub 2020 Nov 2.
    1. Laroni A., Schiavetti I., Sormani M.P., Uccelli A. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult. Scler. 2020 doi: 10.1177/1352458520971817. Nov 181352458520971817.
    1. Loonstra F.C., Hoitsma E., van Kempen Z.L., Killestein J., Mostert J.P. COVID-19 in multiple sclerosis: the Dutch experience. Mult. Scler. 2020;26(10):1256–1260. doi: 10.1177/1352458520942198. Sep.
    1. Louapre C., Collongues N., Stankoff B., Giannesini C., Papeix C., Bensa C., et al. Clinical characteristics and outcomes in patients with Coronavirus Disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77(9):1–10. doi: 10.1001/jamaneurol.2020.2581. June 26.
    1. Louapre C., Maillart E., Papeix C., Zeidan S., Biotti D., Lepine Z., et al. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. ur. J. Neurol. 2020 doi: 10.1111/ene.14612. October 26.
    1. Louapre C., Maillart E., Roux T., Pourcher V., Bussone G., Lubetzki C., et al. Patients with MS treated with immunosuppressive agents: across the COVID-19 spectrum. Rev. Neurol. (Paris) 2020;176(6):523–525. Jun.
    1. Lucchini M., Bianco A., Del Giacomo P., De Fino C., Nociti V., Mirabella M. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report. Mult. Scler. Relat. Disord.. 2020;44 doi: 10.1016/j.msard.2020.102323. June 22.
    1. Luna G., Alping P., Burman J., Fink K., Fogdell-Hahn A., Me Gunnarsson, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, Natalizumab, Rituximab, and injectable therapies. JAMA Neurol. 2019 Available at .
    1. Maghzi A.H., Houtchens M.K., Preziosa P., Ionete C., Beretich B.D., Stankiewicz J.M., et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J. Neurol. 2020:1–7. Jun 3.
    1. Maillart E., Papeix C., Lubetzki C., Roux T., Pourcher V., Louapre C. Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? Mult. Scler. Relat. Disord.. 2020;46 doi: 10.1016/j.msard.2020.102482. September 3.
    1. Mallucci G., Zito A., Fabbro B.D., Bergamaschi R. Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with Fingolimod. Mult. Scler. Relat. Disord.. 2020;45 doi: 10.1016/j.msard.2020.102414. July 19.
    1. Mantero V., Abate L., Balgera R., Basilico P., Salmaggi A., Cordano C. Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients. Mult. Scler. Relat. Disord. 2020;46 doi: 10.1016/j.msard.2020.102453. August 19.
    1. Mantero V., Abate L., Basilico P., Balgera R., Salmaggi A., Nourbakhsh B., Cordano C. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis. J. Neurol. 2020:1–3. doi: 10.1007/s00415-020-10015-1. Jun 25.
    1. Margoni M., Gallo P. Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic. Mult. Scler. J. Exp. Transl. Clin. 2020;6(4) doi: 10.1177/2055217320966346. Oct 122055217320966346.
    1. Matías-Guiu J., Montero-Escribano P., Pytel V., Porta-Etessam J., Matias-Guiu J.A. Potential COVID-19 infection in patients with severe multiple sclerosis treated with Alemtuzumab. Mult. Scler. Relat. Disord. 2020;44 June 11.
    1. Meca-Lallana V., Aguirre C., Río Beatrizdel, Cardeñoso L., Alarcon T., Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult. Scler. Relat. Disord.. 2020;44 June 15.
    1. Mehta D., Miller C., Arnold D., Bame E., Bar-Or A., Gold R., et al. Effect of dimethyl fumarate on lymphocytes in RRMS, Implications for clinical practice. Neurology. 2019;92(15):e1724–e1738. Apr 9.
    1. Mirmosayyeb O., Vaheb S., Barzegar M., Shaygannejad V., Bonavita S., Ghajarzadeh M. Screening neuromyelitis optica patients for COVID-19 infection. Autoimmun. Rev. 2020 doi: 10.1016/j.autrev.2020.102669. Sep 14.
    1. Möhn N., Saker F., Bonda V., Respondek G., Bachmann M., Stoll M., et al. Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse. J. Neurol. 2020:1–3. May 28.
    1. Montero-Escribano P., Matías-Guiu J., Gómez-Iglesias P., Porta-Etessam J., Pytel V., Matias-Guiu J.A. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. Mult. Scler. Relat. Disord. 2020;42 May 7.
    1. Naser Moghadasi A. One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: high Anxiety among MS Patients. Mult. Scler. Relat. Disord. 2020;41 doi: 10.1016/j.msard.2020.102138. JunEpub 2020 April 20.PMID: 32335508.
    1. Nesbitt C., Rath L., Yeh W.Z., Zhong M., Wesselingh R., Monif M., et al. MSCOVID19: using social media to achieve rapid dissemination of health information. Mult. Scler. Relat. Disord. 2020;45 doi: 10.1016/j.msard.2020.102338. June 24Online ahead of print.
    1. Novi G., Mikulska M., Briano F., Toscanini F., Tazza F., Uccelli A., et al. COVID-19 in a MS patient treated with Ocrelizumab: does immunosuppression have a protective role? Mult. Scler. Relat. Disord. 2020;42 Apr 15.
    1. Olivares Gazca J.C., Gómez Almaguer D., Gale R.P., Ruiz Argüelles G.J. Mélange intéressante: COVID-19, autologous transplants and multiple sclerosis. Hematology. 2020;25(1):320. doi: 10.1080/16078454.2020.1802931. Dec.
    1. Parrotta E., Kister I., Charvet L., Sammarco C., Saha V., Charlson R.E., et al. COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol. Neuroimmunol. Neuroinflamm. 2020;7(5):e835. doi: 10.1212/NXI.0000000000000835. July 9.
    1. Preziosa P., Rocca M.A., Nozzolillo A., Moiola L., Filippi M. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. J. Neurol. 2020:1–3. doi: 10.1007/s00415-020-10309-4. Nov 20.
    1. Rezaeimanesh N., Sahraian M.A., Naser Moghadasi A. Evaluation of the opinion of patients with multiple sclerosis on the outcomes of catching COVID-19 and Its effects on the MS symptoms. Basic Clin. Neurosci. 2020;11(2):201–206. doi: 10.32598/bcn.11.covid19.2520.1. Mar-AprEpub 2020 April 20.
    1. Rimmer K., Farber R., Thakur K., Braverman G., Podolsky D., Sutherland L., et al. Fatal COVID-19 in an MS patient on Natalizumab: a case report. Mult. Scler. J. Exp. Transl. Clin. 2020;6(3) doi: 10.1177/2055217320942931. August 102055217320942931.
    1. Safavi F., Nourbakhsh B., Azimi A.R. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult. Scler. Relat. Disord. 2020;43 May 13.
    1. Sahraian M.A., Azimi A., Navardi S., Ala S., Naser Moghadasi A. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult. Scler. Relat. Disord. 2020;46 doi: 10.1016/j.msard.2020.102472. August 29.
    1. Sahraian M.A., Azimi A., Navardi S., Rezaeimanesh N. Naser Moghadasi A. Evaluation of COVID-19 infection in patients with Neuromyelitis Optica spectrum disorder (NMOSD): a report from Iran. Mult. Scler. Relat. Disord. 2020;44 June 1.
    1. Salama S., Giovannoni G., Hawkes C.H., Lechner-Scott J., Waubant E., Levy M. Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis. Mult. Scler. Relat. Disord. 2020;42 Jul.
    1. Seery N., Li V., Nguyen A.L., Roos I., Buzzard K.A., Atvars R., et al. Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia. Mult. Scler. Relat. Disord. 2020;46 doi: 10.1016/j.msard.2020.102516. Sep 16.
    1. Shalhoub S. Interferon beta-1b for COVID-19. Lancet. 2020;395(10238):1670–1671. May 30.
    1. Sharifian-Dorche M., Huot P., Osherov M., Wen D., Saveriano A., Giacomini P.S., et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J. Neurol. Sci. 2020;417 doi: 10.1016/j.jns.2020.117085. October 15.
    1. Soresina A., Moratto D., Chiarini M., Paolillo C., Baresi G., Focà E., et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr. Allergy Immunol. 2020 doi: 10.1111/pai.13263. April 22.
    1. Sormani M.P., De Rossi N., Schiavetti I., Carmisciano L., Cordioli C., Moiola L., et al. disease modifying therapies and Covid-19 severity in Multiple Sclerosis. Lancet Neurol. 2020;19:481–482. d-20-13258.
    1. Stojanov A., Malobabic M., Milosevic V., Stojanov J., Vojinovic S., Stanojevic G., et al. Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak. Mult. Scler. Relat. Disord. 2020;45 doi: 10.1016/j.msard.2020.102407. July 16.
    1. Suwanwongse K., Shabarek N. Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab. Mult. Scler. Relat. Disord. 2020;42 May 15.
    1. Thornton J.R., Harel A. Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with Ocrelizumab. Mult. Scler. Relat. Disord.. 2020;44 doi: 10.1016/j.msard.2020.102341. June 26.
    1. Tomczak A., Han M.H. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study. Mult. Scler. Relat. Disord. 2020;45 doi: 10.1016/j.msard.2020.102347. June 30Online ahead of print.
    1. Valencia-Sanchez C., Wingerchuk D.M. A fine balance: immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. Mult. Scler. Relat. Disord. 2020;42 May 8.
    1. Woo M.S., Steins D., Häußler V., Kohsar M., Haag F., Elias-Hamp B., et al. Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients. J Neurol. 2020:1–3. doi: 10.1007/s00415-020-10046-8. Jul 11.
    1. Wurm H., Attfield K., Iversen A.K., Gold R., Fugger L., Haghikia A. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Mult. Scler. 2020;26(10):1261–1264. doi: 10.1177/1352458520943791. Sep.
    1. Zhang G.X., Sanabria C., Martínez D., Zhang W.T., Gao S.S., Alemán A., et al. Social and professional consequences of COVID-19 lockdown in patients with multiple sclerosis from two very different populations. Neurologia. 2020 doi: 10.1016/j.nrl.2020.08.002. Aug 13S0213-4853(20)30264-4.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever